{'fraction_non_alphanumeric': 0.0440324449594438, 'fraction_numerical': 0.030127462340672075, 'mean_word_length': 5.545454545454546, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 1, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Are ACE inhibitors more effective than ARBs in reducing cardiovascular events in hypertensive patients with diabetes?

ACE inhibitor therapy, compared with placebo or active control, significantly lowers cardiovascular (CV) deaths, myocardial infarction (MI), heart failure (HF), and the composite outcome of CV events in patients with diabetes (SOR: A, consistent metaanalyses of randomized controlled trials [RCTs]). Inconsistent results exist on the effect of ACEI therapy on stroke. No difference is present between angiotensin receptor blockers (ARBs) and active controls on CV deaths, MI, stroke, and the composite outcome of CV events in patients with diabetes (SOR:A, two meta-analyses of RCTs). Inconsistent results exist on the effect of ARBs on HF outcomes. Copyright © 2020 by Family Physicians Inquiries Network, Inc. DOI 10.1097/EBP.0000000000001035